Abstract：Objective To investigate the clinical effect of Albumin-bound Paclitaxel in the treatment of recurrent advanced non-small cell lung cancer.Methods A total of 40 patients with recurrent advanced non-small cell lung cancer treated in Jingjiang People′s Hospital from February 2018 to August 2020 were selected as the research subjects and divided into the study group(20 cases)and the control group(20 cases)according to random number table method.The control group received conventional Paclitaxel chemotherapy regimen,and the study group received Albumin-bound Paclitaxel treatment.The total effective rate,total incidence of adverse reactions and quality of life scores of two groups were compared.Results The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P＜0.05).The incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Before treatment,there was no significant difference in quality of life scores between the two groups(P＞0.05).After treatment,the quality of life scores of the two groups were higher than before treatment,and the study group was higher than the control group,the differences were statistically significant(P＜0.05).Conclusion Treatment with Albumin-bound Paclitaxel in patients with recurrent advanced non-small cell lung cancer has a better effect,which can improve clinical symptoms and quality of life,and has a higher safety,which is worthy of clinical promotion.
京公网安备 11010502046607号